Two experts give an update ahead of the first season with a new mRNA vaccine against flu.

A proposed hepatitis B vaccine trial in Guinea-Bissau raises concerns about delaying newborn protection. This commentary examines the ethical obligations of researchers and the consequences of weakening established prevention efforts.

A proposed $27.7 million reduction in AHRQ funding raises questions about support for infection prevention research and implementation. Here is what the September 25 announcement identifies, as well as what remains unknown about specific IPC programs.

Finding infections earlier is only part of the work. At IDWeek 2026, David Weber, MD, MPH, explored how broader surveillance and emerging technologies could help infection preventionists spend more time supporting safer care.

This week in infection prevention: Kenya’s Bundibugyo virus response shows why execution, not just planning, determines outcomes, and France reported the first known human Shamonda virus infection. Our roundup also covers brucellosis, blood donor screening, and long-acting HIV antibody findings from IDWeek 2026.

At IDWeek 2026, Jimmy Chang, PhD, discussed investigational HIV antibodies TMB-365 and TMB-380, explaining their complementary mechanisms, early study findings, and ongoing evaluation as a long-acting maintenance regimen.

At IDWeek 2026, Samuel Ntow, MBChB, MPH, discussed research findings of reactive infection screening markers in 18.3% of replacement donor records from rural Ghana, highlighting opportunities for further evaluation and linkage to care.

France’s first reported human Shamonda virus infection raises questions about transmission and vulnerable patients. Explore what investigators know, what remains uncertain, and why infection preventionists should follow this emerging story.